Equity · Healthcare
LCTX
AMEXLineage Cell Therapeutics (LCTX)
The line runs 1 USD on 25 September through 1 USD on 30 October, on a scale from 0.90 to 1.05. Days the market did not trade hold the previous close, flat.
- Market cap
- 253.0M USD
- Revenue, year to Dec 2025
- 14.6M USD
- EPS, diluted, year to Dec 2025
- −0.28 USD
- 52-week range
- 0.9027 USD – 2 USD
- Avg volume
- 91.0K
as of Oct 30, 2026
Have Lineage Cell Therapeutics (LCTX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Lineage Cell Therapeutics insiders reported 5 open-market purchases and no sales (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | BROADWOOD PARTNERS, L.P.Director | Buy | 1,000,000 | 771K USD |
| 17 Nov 2026 | Mulroy Michael H.Director | Buy | 30,000 | 26K USD |
| 16 Nov 2026 | Howe Jill AnnChief Financial Officer | Buy | 20,000 | 17K USD |
| 16 Nov 2026 | ANDREWS DEBORAH JDirector | Buy | 25,000 | 20K USD |
| 16 Nov 2026 | Culley Brian MPresident and CEO | Buy | 40,500 | 37K USD |
| Bought | 5 open-market purchases | 1,115,500 | $871K |
Which funds hold Lineage Cell Therapeutics (LCTX)?
7 of the 45 institutional funds we track reported a Lineage Cell Therapeutics position for the quarter ended 30 Sep 2026 — a combined 3.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Held (±25%) | 2,628,150 | 2.5M USD | −12.9% |
| Renaissance Technologies | Trimmed | 674,529 | 645K USD | −49.8% |
| Citadel Advisors | Held (±25%) | 341,881 | 327K USD | −19.8% |
| Marshall Wace | Trimmed | 203,391 | 195K USD | −84.1% |
| Two Sigma Investments | Added | 127,573 | 122K USD | +132.2% |
| Point72 Asset Management | New position | 29,128 | 28K USD | |
| AQR Capital Management | New position | 12,097 | 12K USD |
What has been filed or recorded for Lineage Cell Therapeutics (LCTX)?
The filings we hold for Lineage Cell Therapeutics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,298 shares | 4K USD notional · 0.002% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 24,893 shares | 25K USD notional · 0.010% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 26,826 shares | 24K USD notional · 0.011% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,441 shares | 10K USD notional · 0.004% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.03 USD | Revenue $1M |
| 30 Sep 2026 | Financials | Total assets | 100.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 67.1M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.03 USD | Revenue $1M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.03 USD | Revenue $2M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.28 USD | Revenue $15M |
| 31 Dec 2025 | Financials | Revenue | 14.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −63.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.28 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.13 USD | Revenue $4M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.13 USD | Revenue $3M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.02 USD | Revenue $2M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.09 USD | Revenue $9M |
What do people ask about Lineage Cell Therapeutics (LCTX)?
What did Lineage Cell Therapeutics shares close at?1.00
Lineage Cell Therapeutics closed at 1.00 USD on 30 Oct 2026, down 2.91% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Lineage Cell Therapeutics’ market cap?253.0M
Lineage Cell Therapeutics is worth 253.0M USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Lineage Cell Therapeutics’ revenue?14.6M
Lineage Cell Therapeutics reported revenue of 14.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Lineage Cell Therapeutics insiders bought or sold shares recently?5 purchases
In the 90 days to 22 Nov 2026, Lineage Cell Therapeutics insiders reported 5 open-market purchases and no sales (SEC Form 4). See Insiders
Which funds own Lineage Cell Therapeutics?7 of 45
7 of the 45 funds we track reported a Lineage Cell Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Renaissance Technologies and Citadel Advisors. See Funds
When did Lineage Cell Therapeutics last report earnings?−0.03
Lineage Cell Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.03 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Company websiteAbout text: the company's own website, summarised in our own words